Managing Innovations: Astra Zeneca

The report discusses about managing innovation which is a valuable key to become successful and to survive strongly in this competitive market. Astra Zeneca is a famous global science led bio pharmaceutical business and their innovative medicines are used by millions of patients at worldwide level. With continuous innovation in a company leads towards success in industry.

Managing Innovations
Astra Zeneca

Executive Summary
The report discusses about managing innovation which is a valuable key to become
successful and to survive strongly in this competitive market. Astra Zeneca is a famous global
science led bio pharmaceutical business and their innovative medicines are used by millions of
patients at worldwide level. With continuous innovation in a company leads towards success in
industry. There are different kinds of drugs which has been produced by company for purpose of
curing themselves from diseases to give better life to patients. In this way, it helps in company's
development and innovation in it. With innovation of corona virus vaccine, company has lead
themselves towards next level of success.

Table of Contents
INTRODUCTION...........................................................................................................................4
Future of Industry 2022...................................................................................................................4
Astra Zeneca Innovation requirement 2022 and beyond.................................................................6
Building the Future Innovation Capabilities for the Organisation...................................................7
CONCLUSION..............................................................................................................................10
REFERENCES..............................................................................................................................12

INTRODUCTION
Innovation management can be defined in a manner that basically innovation word comes
from Latin word “innovare” and which stands for renewal. Innovation is something which brings
benefits for an organization from economic point of view. In a overall manner, innovation
management is a systematic promotion of innovation within organization and which includes
tasks of planning, control, organisation and management. Innovation management leads towards
new products and services for conquering new markets. New products and services gives leads in
standing out differently in competitive market (Tsangari, H. and Mantara, I., 2021). Changes in
internal processes also help in strengthening the company from internal perspective and also
contributes in saving costs. Due to innovation in company it gives opportunity for generation of
new business models to use new source of income. Purpose of this report is in context of
innovation in Astra Zeneca company with respect to medicines and different kinds of drugs
produced by company. Company follows the hierarchical structure where there is a very large
team and which works under different department and under various kinds of position. It can be
categorised in form of chairman, vice president, manager, junior manager and staff members or
employees. That's why in such a large company this type of structure has been followed by
company.
Future of Industry 2022
From perspective of future of pharmaceutical industry, with innovation in technology and
different kinds of emerging trends leads towards big success of industry. Emerging trends like
robotics, artificial intelligence, 3D printing, precision medicine and patient design will have an
impact on manufacturing and distribution of pharmaceuticals. In the current year, pharma
industry has been growing with the triple speed in terms of innovation as well as selling of their
products and services. With support of innovation in industry also leads towards the greater life
expectancy of patients and people who are associated with this field in this pandemic situation as
well. Due to corona virus situation, it has been observed that some new diseases and viruses have

been emerging on a regular basis(Kela-Madar, N. and Kela, I., 2019).For that purpose pharma
industry is producing new drugs and medicines which has never been produced on earlier basis.
Company also using innovative techniques like use of chip which has been inserted in human
body and with support of that BP can be measured easily. With support of biotechnology
companies and innovation done by companies gives a relief to different kinds of patients.
Different kinds of drugs produced by company gives innovation to market as well as create great
future for company (Gavine, and et.al., 2015). The future of this particular industry is very bright
because according to current situation when whole world is dealing with lots of diseases then
they need compulsory innovation for curing patients from diseases. Due to lots of research and
development new drugs, medicines and vaccines have been created and this has been sold out on
a large scale. Due to which this industry will earn large amount of profits as well as generate
revenue for country from larger spectrum. When lots of investment and collaboration has been
done on international level in this industry. As a result, from overall world perspective every
country makes good relation with each other and every country's pharma sector gets improved as
compared to their previous situation. That's why this industry becomes very important from
terms of business as well as for welfare of people. In this way, it has grown in an out of box
manner.
Companies in UK country under pharma industry, generates around market value of
£21bn. Due to which this industry is growing at a very faster pace and in terms of future there
will be more use of robots in place of nurses and other staff. It has been observed that there are
some diseases will emerge in future where it has spread on a faster pace and majorly on basis of
communicable level. So its beneficial that major use of robots and technology will help in saving
people from these kind of diseases(Pollach, I., 2015). From perspective of next year, pharma
brings together heads of brands and franchises, marketing, sales and digital executives. Business
of this sector has been increasing on a very large scale and earns in an out of box manner.
Astra Zeneca Innovation requirement 2022 and beyond
According to Asta Zeneca company, their focus is totally on enhanced innovation and
delivery of life changing medicines for patients which contribute towards society. They focus on
three main therapies which are named as Oncology, Cardiovascular, Renal and metabolism and

respiratory diseases. In terms of future growth of company, they are more responding towards
growth through innovation. This can be possible through by being more patient-centric, doing
more work with technology, digital and data and advancing more towards cutting-edge science.
Vaccine launched by the company for corona virus is also showing that the use of AZD1222
according to WHO is recommended even at presence of different virus variant. With context of
this disease, company has to work continuously for new variants with respect to innovative
vaccine(Hew, M. and Reddel, H. K., 2019). So that in case present vaccine does not work for
longer period of time then from future perspective company has to work on new vaccine and
need to do research on it.
In terms of innovation they have to produce vaccine in such a manner that patient can
themselves use it and insert it by full confidence level in their body. Small kits of medicines and
drugs have been created so that patient does not find it very difficult in using it. Because there
are various competitive companies who give tough competition to Astra Zeneca. For future
development, they have to work on medicine development and gives acceleration to launch of
products by company. Their aim is also that new medicine localisation needs to be done. They
also have a plan to create fully integrated ecosystems(Chrystyn, H. and Lavorini, F., 2020).
Patient-centric approach is their first priority. Company has also focused on emerging market
strategy so that whatever innovation they have done can be sold out on a very large scale. They
have adopted three pillar strategy which includes expansion, innovation and partnership.
Expansion can be done in terms of portfolio selling, retail, customer base and increasing market
access. In terms of increasing market access they have to do promotion on large level and also
have recommendation of particular medicines from recognised doctors. So that people can trust
them and purchase it on a large scale. They have to work in a strategical manner with respect to
retail sector.
Company also made plans with respect to partnership way. They have to make strategy for
making partnership with central and local government(Reiss, and et.al., 2021). Company has to
make good terms with local healthcare providers and local capital markets so that their
innovation products can be sold out on a large scale. For developing business they have to make
strategy for making good terms with people associated with healthcare. In this way through
contacts and renowned people help in selling out products on a large scale. By adapting all these

strategies, planning and management company can grow on a very large scale. And their
innovation also make good stand in market for attracting large number of customers and retailers
also.
Building the Future Innovation Capabilities for the Organisation
With respect to Astra Zeneca company, it is a company which is a British-Swedish
multinational pharmaceutical and biotechnology company. This company was founded in year of
1991. It is headquartered at Cambridge biomedical campus in Cambridge, England. This is a
company which is established at global level and which is involved in science-led
biopharmaceutical business(Chan, and et.al., 2020). Their innovative medicines have been used
by millions of patients at worldwide level. This company has portfolio of products for major
diseases. It includes oncology, cardiovascular, gastrointestinal, infection, neuroscience,
respiratory and inflammation. Their purpose and values are in terms of explaining why they
exist, what they hope to accomplish, the behaviours which they value, how they achieve their
goals and their promise towards their stakeholders.
Future innovation capabilities has been developed through research and development and by
applying various methods and tests. For this kind of development it has been require lots of
planning, strategies so that it can give something unique to market and also stand strongly
against their competitor at international level. Currently they are focusing on enhanced
innovation and delivery of life changing medicines for patients which contribute towards society.
They focus on three main therapies which are named as Oncology, Cardiovascular, Renal and
metabolism and respiratory diseases. In terms of future growth of company, they are more
responding towards growth through innovation. This can be possible through by being more
patient-centric, doing more work with technology, digital and data and advancing more towards
cutting-edge science (Benusiglio, and et.al., 2019). The organisation nature is that to deliver their
strategic priorities in a sustainable manner. They support continuously for scientific innovation
and commercial success. Their main aim is that to discover, develop and commercialise the
prescription of medicines in particular sectors.
The Mckinsey 7S model is a management model which has been developed by business
consultants and it was a strategic vision for groups. It is a kind of tool which helps in analysing a

company’s organisational design. The structure of this model includes 7S which are named as
structure, strategy, systems, skills, style, staff and shared values.
 Structure: This head talks about the way in which a company needs to be organized.
Astra Zeneca has a flatter organisational hierarchy which is supported by learning and
progressive organisations. In terms of innovation this type of structure supports in
quicker decision making process.
 Strategy: Under this head, it defines about strategic direction and business definition of
strategy which has been clearly defined and communicated to all the employees and
stakeholders. In terms of innovation, with support of strategic direction helps the business
to guide their employees, staff and their stakeholders.
 Systems: Under this head, company’s system should be designed in such a manner that
there are no conflicts or disputes and also ensures about business operations. In terms of
innovation, Astra Zeneca has to design their system into different departmental nature so
that it can be adaptable by the overall organisation.
 Skills: Under this head it talks about skills of their employees and everyone who is
working into an organisation and all of them should be perfect in their field according to
current requirement of market. In terms of innovation, Astra Zeneca has to update their
employees with different kinds of skills so that they can easily adapt those changes.
 Style: Under this head, it talks about particular type of leadership style which needs to be
implemented according to the organisational nature. AstraZeneca has participative style
of leadership where every employee is involved into decision making process whether it
is related to innovation or about further growth of company.
 Staff: Astra Zeneca staff members should be of flexible and adaptive nature so that they
can handle any kind of innovation and changes into organisational context.
 Shared Values: The core values of Astra Zeneca company are defined and communicated
for fostering a creative and supportive organisational structure which allows employees
to perform optimally and enhance their commitment and motivation.
With respect to Astra Zeneca company, innovation capabilities can be developed into certain
steps by setting an aim for it. After that define goals and objectives for it so that roadmap
becomes clear that what they want to achieve. After that next step is that an individual has to

perform diagnostics in a deeper manner for purpose of highlighting quick wins and gaps of
innovation capability.
Next step is towards designing components related to future innovation system. After that there
is a requirement to develop innovating professionals. And in the last step with support of phased
approach, plan and embed the innovation system. In this way, innovation capabilties have been
developed into a proper manner(Ifidon, and et.al., 2020).Astra zeneca has to evaluate their
competitors that what they are doing which makes them different from other organisation. They
have to launch such vaccine that they can fight against any kind of variant come in future with
respect to corona virus. They can also work towards that kind of medicine which can be in
powdered form and it can be taken in the similar manner of ORS. So that customers need not to
face any kind of problem while taking medicine. They can also work towards making robots and
increase use of artificial intelligence so that staff members need not to go frequently in rooms of
patient. In this way, they can protect their staff members from getting infected. They can
initiative towards making medicine in sweeter form so that patients do not feel anxiety while
taking medicine. Through this kind of innovation it act as a different parameter in the
international market.
They can develop certain kind of technology or drugs in future which can be inserted into human
body and it can strongly fight against any kind of communicable disease. For developing
immune system in a stronger manner they can create a particular medicine which have a long
term or life long impact on human body. Due to which people can relax themselves and freely
go anywhere without any hesitation and also they do not need to worry about their immune
system. For becoming stronger in market they can come up with those kind of innovation which
no one has heard before (Perri, A., 2015). Company can also take initiative with respect to
patient concern that they can test themselves at their home and no need to go anywhere in
hospitals. They can also aim for those kind of vaccine which do not have null after effects so that
people do not hesitate in taking vaccine. From future perspective and future generated diseases it
is required that company can launch such kinds of products which can be taken along with food
as a daily routine.
Capabilities of the company can be evaluated through how much research and development and
investment has been done by company. How much pain and efforts has been taken by company
is evaluated in form of their results.

Time spend in doing research also defines about quality of products launched by the company.
Because in research every aspect needs to be considered so that every type of people can take
innovation by company in a positive manner.
For building a positive future it is important that they think about coming problems and un for
seen situation and this can be possible through advanced technology on a higher level. Astra
zeneca company can also take special efforts for old age people by developing such kind of
medicines so that it can increase their life expectancy level also (Basu, R., 2015). Because old
age people are those kind of age group where they have to face maximum problems with respect
to their health. In this way, company can take efforts with respect to their innovation capabilities
and comes with new ideas into market at international level. By doing these kind of activities it
will inspire other companies of this particular industry for doing innovation and lead towards
growth of economy as well as into this particular industry.
With respect to Astra Zeneca company, beyond research and development and research
partnerships, the boundaries of science have been pushed together. Company has spend lots of
their time in creating unique enabling tools and technologies. It is with respect to interest area of
scientific community of investigators. In terms of building innovation capability of organisation,
first of all establish a programme of change for purpose of building organisational capability.
Then it is need to identify a senior champion and initiate top down implementation. Next step is
towards management buy-in from perspective of excitement(Khunti, and et.al., 2020).After that
with support of recognition and reward it is required that to incentivise with value-focused
behaviours. And last step is that for maximising effectiveness, focus should be on identifying
areas of greatest needs. Company can also take initiative with respect to producing those kind of
techniques and medicines which support in easier birth of child and women get easily pregnant.
In this way, it gives solution to various kind of people who faces this particular type of
challenge. This kind of innovation helps in various aspect for starting their family and women
can also live in a free will manner without any hesitation.
For building innovation capability company has to study various aspects where they need to
analyse that what is current requirement of market and also need to do research about what types

of problems have been faced by human body in this current environment. Also need to analyse
about in which area problems can be emerged in future.
Company can also take steps towards producing advance level of medicines with respect to
mental problems or mental health problems. In this current scenario, everybody is facing some
particular kind of challenges, tension in their day to day life(Gatwood, and et.al., 2021). Due to
which some people comes under category of depression where individual does not about it. In
this manner, they have to face various kinds of challenges which people do not aware about the
particular reason of it. So company's innovative medicines and techniques can help patients and
other people in getting out of their problems and challenges.
Company can also take initiative in building those particular kind of techniques which help in
regeneration of body parts of human being. In this current scenario where due to cancer
treatment and in war like situation where people have lost some of their body parts. So company
can take step towards in producing those kind of medicines which help in regeneration of body
parts. It can be in form of slower regeneration of body parts. With this kind of support people
now have new enthusiasm towards their life(Lukic, and et.al., 2016). After launch of these kind
of techniques and medicines people now have satisfaction and new hope that their life
expectancy rate can be increased in a positive manner. In this way, future innovation capabilities
can be developed by company and increase their growth in terms of positive manner.
CONCLUSION
Managing innovation in an organisation is not an easy task. Because innovation needs
lots of research, development and study. Due to which results come out of it takes lots of time,
planning and efforts. In terms of Astra Zeneca company, it has been observed that they have
launched vaccine and other medicine for corona virus which somewhere act as in a successful
manner. For doing innovation by company , it is important that they need to analyse about what
is current requirement of market and also need to study about human body. Through having
study related to it gives idea about that in which area they need to work so that they can give best
results and unique products at international level. These products can be in form of medicines,
vaccines and new techniques. For managing innovation they can use advance technology which
supports them in producing exceptional products and come out as a unique thing in market.
Innovation is something which has been created within the existing product and needs lots of

research for analysing about every aspect of it. In an organisation, innovation can be managed
through various parameters by taking care about its each and every aspect.
Company has to be very smart and proactive in nature so that it can compete at international
level in a stronger way. For giving tough competition to other companies they have to also take
care about what other companies are doing which makes them unique from other.

REFERENCES
Books and Journals
Lukic, and et.al., 2016. Research and Development Costs in Retail Trade. Management and
Economic Review, 1(2), pp.170-182.
Gatwood, and et.al., 2021. Alignment of diagnosis and pharmacy claims data coding of
medication adherence among patients with diabetes or hypertension. Journal of
Managed Care & Specialty Pharmacy, 27(4), pp.497-506.
Khunti, and et.al., 2020. The importance of the initial period of basal insulin titration in people
with diabetes. Diabetes, Obesity and Metabolism, 22(5), pp.722-733.
Basu, R., 2015. Managing projects in research and development. Ashgate Publishing, Ltd..
Perri, A., 2015. Innovation and the multinational firm: Perspectives on foreign subsidiaries and
host locations. Springer.
Ifidon, and et.al., 2020. Improving racial and ethnic minority representation in cardiovascular
disease trials to advance health equity. JAMA cardiology, 5(5), pp.611-611.
Benusiglio, and et.al., 2019. Germline Variants in Highly Selected Patients With Prostate
Cancer. JAMA oncology, 5(9), pp.1367-1368.
Chan, and et.al., 2020. SABA Reliance Questionnaire (SRQ): Identifying Patient Beliefs
Underpinning Reliever Overreliance in Asthma. The Journal of Allergy and Clinical
Immunology: In Practice, 8(10), pp.3482-3489.
Reiss, and et.al., 2021. Phase II Study of Maintenance Rucaparib in Patients With Platinum-
Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in
BRCA1, BRCA2, or PALB2. Journal of Clinical Oncology, pp.JCO-21.
Hew, M. and Reddel, H. K., 2019. Integrated adherence monitoring for inhaler
medications. Jama, 321(11), pp.1045-1046.
Pollach, I., 2015. Strategic corporate social responsibility: the struggle for legitimacy and
reputation. International Journal of Business Governance and Ethics, 10(1), pp.57-75.
Gavine, and et.al., 2015. Identification and validation of dysregulated MAPK7 (ERK5) as a
novel oncogenic target in squamous cell lung and esophageal carcinoma. BMC
cancer, 15(1), pp.1-9.
Kela-Madar, N. and Kela, I., 2019. The Machine-Human Collaboration in Healthcare
Innovation. Toward Super-Creativity-Improving Creativity in Humans, Machines, and
Human-Machine Collaborations.
Tsangari, H. and Mantara, I., 2021. Brexit Calling! Aftermath in the Pharmaceutical
Industry. International Journal of Business, 8(2), pp.70-80.
Chrystyn, H. and Lavorini, F., 2020. The dry powder inhaler features of the Easyhaler that
benefit the management of patients. Expert review of respiratory medicine, 14(4),
pp.345-351.